PARADIGM BIOCAPITAL ADVISORS LP Holdings

PARADIGM BIOCAPITAL ADVISORS LP is an investment fund managing more than 750.14M US dollars. The largest holdings include Global Blood Therapeutics, Mirati Therapeutics and Incyte. In Q3 2022 the fund bought assets of total value of 251.89M US dollars and sold assets of total value of 729K US dollars.

$750.13M

portfolio value

+14.21%

quarter

PARADIGM BIOCAPITAL ADVISORS LP portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q1 2022	149404000	97983000
Q2 2022	214915000	94044000
Q3 2022	251894000	729000

PARADIGM BIOCAPITAL ADVISORS LP 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Biotechnology Global Blood Therapeutics, Inc. Portfolio share: 10.68% Portfolio value: 80.07M Avg. open price: $33.3 Current price: $68.49 P/L: +105.67% Sold -18.66% shares Q3 2022	share	10.68%	80.07M	$33.3	$68.49	+105.67%	Sold -18.66% shares Q3 2022
Biotechnology Mirati Therapeutics, Inc. Portfolio share: 7.92% Portfolio value: 59.39M Avg. open price: $78.4 Current price: $92.75 P/L: +18.31% Bought +28.85% shares Q3 2022	share	7.92%	59.39M	$78.4	$92.75	+18.31%	Bought +28.85% shares Q3 2022
Biotechnology Incyte Corporation Portfolio share: 6.87% Portfolio value: 51.51M Avg. open price: $78.03 Current price: $84.08 P/L: +7.75% Bought +39.03% shares Q3 2022	share	6.87%	51.51M	$78.03	$84.08	+7.75%	Bought +39.03% shares Q3 2022
Biotechnology Ascendis Pharma A/S Portfolio share: 6.85% Portfolio value: 51.35M Avg. open price: $118.72 Current price: $119.41 P/L: +0.58% Bought +15.08% shares Q3 2022	share	6.85%	51.35M	$118.72	$119.41	+0.58%	Bought +15.08% shares Q3 2022
Biotechnology Legend Biotech Corporation Portfolio share: 5.86% Portfolio value: 43.92M Avg. open price: $47.66 Current price: $50.99 P/L: +7.00% Bought +10.01% shares Q3 2022	share	5.86%	43.92M	$47.66	$50.99	+7.00%	Bought +10.01% shares Q3 2022
Drug Manufacturers—General Biogen Inc. Portfolio share: 5.50% Portfolio value: 41.28M Avg. open price: N/A Current price: $292.75 P/L: N/A N/A Q3 2022	share	5.50%	41.28M	N/A	$292.75	N/A	N/A Q3 2022
Drug Manufacturers—General Biogen Inc. Portfolio share: 5.34% Portfolio value: 40.05M Avg. open price: N/A Current price: $292.75 P/L: N/A N/A Q3 2022	call	5.34%	40.05M	N/A	$292.75	N/A	N/A Q3 2022
Biotechnology Immunocore Holdings plc Portfolio share: 4.84% Portfolio value: 36.28M Avg. open price: $33.52 Current price: $58.07 P/L: +73.21% Bought +15.83% shares Q3 2022	share	4.84%	36.28M	$33.52	$58.07	+73.21%	Bought +15.83% shares Q3 2022
Biotechnology Viridian Therapeutics, Inc. Portfolio share: 4.47% Portfolio value: 33.55M Avg. open price: $13.35 Current price: $26.84 P/L: +101.06% Bought +25.23% shares Q3 2022	share	4.47%	33.55M	$13.35	$26.84	+101.06%	Bought +25.23% shares Q3 2022
Biotechnology argenx SE Portfolio share: 4.25% Portfolio value: 31.87M Avg. open price: $378.88 Current price: $393.21 P/L: +3.78% Bought +1.67% shares Q3 2022	share	4.25%	31.87M	$378.88	$393.21	+3.78%	Bought +1.67% shares Q3 2022
Biotechnology United Therapeutics Corporation Portfolio share: 3.92% Portfolio value: 29.43M Avg. open price: $179.41 Current price: $273.72 P/L: +52.57% Sold -13.80% shares Q3 2022	share	3.92%	29.43M	$179.41	$273.72	+52.57%	Sold -13.80% shares Q3 2022
Biotechnology Akero Therapeutics, Inc. Portfolio share: 3.78% Portfolio value: 28.37M Avg. open price: N/A Current price: $44.04 P/L: N/A N/A Q3 2022	share	3.78%	28.37M	N/A	$44.04	N/A	N/A Q3 2022
Biotechnology Bicycle Therapeutics plc Portfolio share: 3.59% Portfolio value: 26.95M Avg. open price: $16.78 Current price: $32.41 P/L: +93.15% Bought +10.51% shares Q3 2022	share	3.59%	26.95M	$16.78	$32.41	+93.15%	Bought +10.51% shares Q3 2022
Biotechnology Syndax Pharmaceuticals, Inc. Portfolio share: 3.48% Portfolio value: 26.07M Avg. open price: $19.72 Current price: $25.44 P/L: +28.98% Bought +23.85% shares Q3 2022	share	3.48%	26.07M	$19.72	$25.44	+28.98%	Bought +23.85% shares Q3 2022
Biotechnology Axsome Therapeutics, Inc. Portfolio share: 3.09% Portfolio value: 23.20M Avg. open price: N/A Current price: $77.29 P/L: N/A N/A Q3 2022	share	3.09%	23.20M	N/A	$77.29	N/A	N/A Q3 2022
Drug Manufacturers—General Horizon Therapeutics Public Limited Company Portfolio share: 2.90% Portfolio value: 21.74M Avg. open price: N/A Current price: $98.48 P/L: N/A N/A Q3 2022	share	2.90%	21.74M	N/A	$98.48	N/A	N/A Q3 2022
Biotechnology Alpine Immune Sciences, Inc. Portfolio share: 2.13% Portfolio value: 15.94M Avg. open price: $8.63 Current price: $6.78 P/L: -21.50% Bought +167.87% shares Q3 2022	share	2.13%	15.94M	$8.63	$6.78	-21.50%	Bought +167.87% shares Q3 2022
Biotechnology Prothena Corporation plc Portfolio share: 1.91% Portfolio value: 14.29M Avg. open price: N/A Current price: $60.39 P/L: N/A N/A Q3 2022	share	1.91%	14.29M	N/A	$60.39	N/A	N/A Q3 2022
Biotechnology Arvinas, Inc. Portfolio share: 1.68% Portfolio value: 12.62M Avg. open price: $78.53 Current price: $39.53 P/L: -49.66% Sold -45.15% shares Q3 2022	share	1.68%	12.62M	$78.53	$39.53	-49.66%	Sold -45.15% shares Q3 2022
Drug Manufacturers—Specialty & Generic Esperion Therapeutics, Inc. Portfolio share: 1.54% Portfolio value: 11.52M Avg. open price: $5.36 Current price: $7.49 P/L: +39.62% Bought +22.14% shares Q3 2022	share	1.54%	11.52M	$5.36	$7.49	+39.62%	Bought +22.14% shares Q3 2022
Biotechnology Merus N.V. Portfolio share: 1.51% Portfolio value: 11.30M Avg. open price: $25.09 Current price: $14.2 P/L: -43.40% Bought +24.76% shares Q3 2022	share	1.51%	11.30M	$25.09	$14.2	-43.40%	Bought +24.76% shares Q3 2022
Biotechnology G1 Therapeutics, Inc. Portfolio share: 1.47% Portfolio value: 11.04M Avg. open price: N/A Current price: $6.17 P/L: N/A N/A Q3 2022	share	1.47%	11.04M	N/A	$6.17	N/A	N/A Q3 2022
Biotechnology Crinetics Pharmaceuticals, Inc. Portfolio share: 1.36% Portfolio value: 10.19M Avg. open price: N/A Current price: $18.32 P/L: N/A N/A Q3 2022	share	1.36%	10.19M	N/A	$18.32	N/A	N/A Q3 2022
Biotechnology Oyster Point Pharma, Inc. Portfolio share: 1.24% Portfolio value: 9.26M Avg. open price: $13.65 Current price: $11.11 P/L: -18.60% Bought +23.62% shares Q3 2022	share	1.24%	9.26M	$13.65	$11.11	-18.60%	Bought +23.62% shares Q3 2022
Biotechnology TG Therapeutics, Inc. Portfolio share: 1.19% Portfolio value: 8.91M Avg. open price: N/A Current price: $8.16 P/L: N/A Sold -23.37% shares Q3 2022	share	1.19%	8.91M	N/A	$8.16	N/A	Sold -23.37% shares Q3 2022
Biotechnology Poseida Therapeutics, Inc. Portfolio share: 0.97% Portfolio value: 7.30M Avg. open price: N/A Current price: $5.1 P/L: N/A N/A Q3 2022	share	0.97%	7.30M	N/A	$5.1	N/A	N/A Q3 2022
Biotechnology Vor Biopharma Inc. Portfolio share: 0.90% Portfolio value: 6.78M Avg. open price: $7.09 Current price: $4.72 P/L: -33.39% Bought +30.62% shares Q3 2022	share	0.90%	6.78M	$7.09	$4.72	-33.39%	Bought +30.62% shares Q3 2022
Biotechnology Milestone Pharmaceuticals Inc. Portfolio share: 0.78% Portfolio value: 5.82M Avg. open price: N/A Current price: $4.75 P/L: N/A N/A Q3 2022	share	0.78%	5.82M	N/A	$4.75	N/A	N/A Q3 2022
Biotechnology C4 Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $32.88 Current price: $8.28 P/L: -74.82% Sold -100.00% shares Q3 2022	share	0.00%	0	$32.88	$8.28	-74.82%	Sold -100.00% shares Q3 2022
Biotechnology Liquidia Corporation Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $5.18 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$5.18	N/A	Sold -100.00% shares Q3 2022
Biotechnology Gracell Biotechnologies Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $6.36 Current price: $2.87 P/L: -54.87% Sold -100.00% shares Q3 2022	share	0.00%	0	$6.36	$2.87	-54.87%	Sold -100.00% shares Q3 2022
Biotechnology Enanta Pharmaceuticals, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $43.06 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$43.06	N/A	Sold -100.00% shares Q3 2022
Biotechnology Sierra Oncology, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $23.38 Current price: $54.99 P/L: +135.22% Sold -100.00% shares Q3 2022	share	0.00%	0	$23.38	$54.99	+135.22%	Sold -100.00% shares Q3 2022

Showing TOP 33 PARADIGM BIOCAPITAL ADVISORS LP's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of PARADIGM BIOCAPITAL ADVISORS LP?

The biggest position of the PARADIGM BIOCAPITAL ADVISORS LP is Global Blood Therapeutics, Inc. (GBT) with 10.68% portfolio share worth of 80.08M US dollars.

Top 5 PARADIGM BIOCAPITAL ADVISORS LP's holdings represent 38.16% of the portfolio:

Global Blood Therapeutics, Inc. (GBT) – 10.68%
Mirati Therapeutics, Inc. (MRTX) – 7.92%
Incyte Corporation (INCY) – 6.87%
Ascendis Pharma A/S (ASND) – 6.85%
Legend Biotech Corporation (LEGN) – 5.86%

Who is the portfolio manager of PARADIGM BIOCAPITAL ADVISORS LP?

The portfolio manager of the PARADIGM BIOCAPITAL ADVISORS LP is .

What is the total asset value of the PARADIGM BIOCAPITAL ADVISORS LP portfolio?

PARADIGM BIOCAPITAL ADVISORS LP total asset value (portfolio value) is 750.14M US dollars.

Who is ?

is the portfolio manager of the PARADIGM BIOCAPITAL ADVISORS LP.

What is (PARADIGM BIOCAPITAL ADVISORS LP) fund performance?

PARADIGM BIOCAPITAL ADVISORS LP's quarterly performance is +14.21%, annualy 0.00%.

What is the PARADIGM BIOCAPITAL ADVISORS LP CIK?

PARADIGM BIOCAPITAL ADVISORS LP's Central Index Key is 0001855655 .